COMMUNIQUÉS West-GlobeNewswire

Apricus Biosciences Announces FDA Acknowledgement of Vitaros(TM) Class 2 NDA Resubmission
31/08/2017
PDUFA Goal Date of February 17, 2018 SAN DIEGO, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today [...]
MPI: MPI publishes Half-year Report for the first half of 2017
31/08/2017
Hoersholm, Denmark, August 31, 2017 - Medical Prognosis Institute A/S ("MPI") announces the company's Half-year report for the period January-June 2017. The report is available as an attached document to this press [...]
Xbrane Biopharma releases interim report for the period April - June 2017
31/08/2017
Press release 2017-08-31 Xbrane Biopharma ABs interim report for the period April - June 2017 is now available on the Company's website, www.xbrane.com . April to June Net sales SEK 4,514 thousand (1,032) Total income [...]
Ambu A/S: Articles of Association August 2017
31/08/2017
Articles of Association August 2017 This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely [...]
Ambu A/S: Capital increase in connection with exercise of warrants issued
31/08/2017
Company announcement no. 16_2016_17 This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely [...]
Total number of shares and voting rights in Zealand at August 31, 2017
31/08/2017
Company announcement - No. 42 / 2017 Total number of shares and voting rights in Zealand at August 31, 2017 Copenhagen, August 31, 2017 - In accordance with Section 10 of the Danish Statutory Order on Issuers' [...]
Symphogen A/S: Symphogen presents promising results from a randomized Phase 2 study with Sym004 at ESMO 2017 Congress
31/08/2017
Symphogen presents promising results from a randomized Phase 2 study with Sym004 at ESMO 2017 Congress Oral presentation of efficacy and safety data of Sym004 in refractory metastatic colorectal cancer COPENHAGEN, [...]
ESPERITE (ESP): L1 Capital subscribes to the Seventh tranche of investment today
31/08/2017
Zutphen, The Netherlands, 31 August 2017 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today the Seventh Tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the " [...]
Biocartis Group NV: Biocartis announces 2017 half-year results on 7 September 2017
31/08/2017
PRESS RELEASE - REGULATED INFORMATION Thursday, 31 August 2017, 07:01 CEST BIOCARTIS ANNOUNCES 2017 HALF-YEAR RESULTS ON 7 SEPTEMBER 2017 Mechelen, Belgium , 31 August 20 17 - Biocartis Group NV (the 'Company' or ' [...]
Biocartis Group NV: Strong performance data of proprietary MSI Biomarkers for the Idylla(TM) MSI Test to be published at ESMO
31/08/2017
PRESS RELEASE: 31 August 2017, 07:00 CEST Strong performance data of proprietary MSI Biomarkers for the Idylla(TM) MSI Test to be published at ESMO Mechelen, Belgium, 31 August 2017 - Biocartis Group NV (the 'Company' [...]
Probiodrug reports financial results for H1 2017 and corporate update
31/08/2017
Probiodrug reports financial results for H1 2017 and corporate update PQ912 delivers positive pharmacodynamic and efficacy results in a Phase-2a study in early stage AD patients Successful settlement of long-pending tax [...]
MDxHealth Announces First Half 2017 Financial Results
31/08/2017
Total revenue up 87%, product revenue up 10% and 44% increase in test volume NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, August 31, 2017 - MDxHealth SA ( [...]
MDxHealth publie ses résultats financiers pour le premier semestre 2017
31/08/2017
Augmentation des recettes totales de 87 %, des recettes du produit de 10 % et 44 % de volume de tests en plus COMMUNIQUÉ DE PRESSE / INFORMATIONS RÉGLEMENTÉES / INFORMATION PRIVILEGIEE IRVINE, CA, et HERSTAL, BELGIQUE [...]
Vistin Pharma ASA : Second quarter 2017 results - continuing strong demand for metformin
31/08/2017
Norwegian pharmaceutical company Vistin Pharma ASA (OSE: VISTIN) experienced strong demand and stable prices for its metformin products in the second quarter of 2017. Upon completion of the recently announced sale of [...]
VALNEVA : Résultats financiers solides & Progrès R&D majeurs au S1 2017
31/08/2017
Valneva: Résultats financiers solides & Progrès R&D majeurs au S1 2017 La société poursuit sa forte performance commerciale tout en se concentrant sur l'avancée de ses principaux programmes de R&D Résultats [...]
VALNEVA: Reports Robust H1 2017 Financial Results & Major R&D Progress
31/08/2017
Valneva Reports Robust H1 2017 Financial Results & Major R&D Progress Company Continues Delivering Strong Commercial Performance while Focusing on Advancing Leading R&D Programs Robust H1 2017 Financial [...]
Santhera Announces Approval of Raxone® for LHON in Israel
31/08/2017
Liestal, Switzerland, August 31, 2017 - Santhera Pharmaceuticals (SIX: SANN) announces approval of Raxone ® (idebenone) for the treatment of visual impairment in adolescent and adult patients with Leber's hereditary [...]
Bone Therapeutics announces H1 results for 2017
31/08/2017
Regulated information The interim financial report is prepared in accordance with article 13 of the Royal Decree on the obligations of issuers of financial instruments admitted to trading on a regulated market and can [...]
Bone Therapeutics publie ses résultats du premier semestre 2017
31/08/2017
Information réglementée Le rapport semestriel est préparé conformément au prescrit de l'article 13 de l'Arrêté Royal relatif aux obligations des émetteurs d'instruments financiers admis à la négociation sur un marché [...]

Pages